FDA-Regulated Firms Press High Court To Limit Adverse Event Reporting
As the Supreme Court prepares to examine whether medical product developers and life science firms must disclose all reported adverse events -- not only those situations with a confirmed link to a drug, device or dietary supplement -- to investors, a large swath of FDA-regulated industries are pressing the nation's top justices to reverse a lower court ruling that they say runs counter to a 1995 securities law aimed at reducing litigation.
You've followed a link to an article or document on InsideHealthPolicy.com.
There are three ways you can access this content.
Subscriber Login
If you are an InsideHealthPolicy.com subscriber, or you have an active trial subscription, please login here:
Take A Trial Subscription
If you haven't already had a trial subscription to InsideHealthPolicy.com, you can sign up for one right now. Just click on the link below to get started -- you'll get full access for one month, including access to our newsletters, Inside CMS and FDA Week, plus daily news updates by e-mail and much, much more.
Buy This Article
You can also buy this and other individual InsideHealthPolicy.com articles by going to the InsideHealthPolicy.com NewsStand. Articles are $5 apiece. We'll even give you your first download free.
Here's a direct link to this article on the NewsStand.